JPMorgan Reinstates Mirum Pharmaceuticals (MIRM) at Overweight
JPMorgan analyst Jessica Fye reinstates coverage on Mirum Pharmaceuticals (NASDAQ: MIRM) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
